文献速递肝病

新型乙肝相关慢加急性肝衰竭预后评分开发与验证

Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure.
PubMed 文献 · J Hepatol · 2021-06-04

基于2409例住院患者的前瞻性数据开发新型简化预后评分,并在954例符合COSSH-ACLF标准的HBV-ACLF患者中验证。新评分含6项预测因子,28/90天死亡率C指数为0.826/0.809,显著高于COSSH-ACLF、CLIF-C ACLF、MELD和MELD-Na,外部队列验证结果一致。

要点

  • 新评分由INR、肝性脑病评分、中性粒细胞、总胆红素、血清尿素和年龄6项因子构成。
  • 新评分28/90天死亡率C指数0.826/0.809,优于COSSH-ACLF、CLIF-C ACLF、MELD和MELD-Na。
  • 新评分无需评估器官衰竭,可准确预测HBV-ACLF患者短期死亡率。

核心结论

  • 基于6项预测因子且无需评估器官衰竭的新评分能准确预测HBV-ACLF患者短期死亡率,可能用于指导临床管理。

研究设计与样本

  • 前瞻性临床数据来自2409例因HBV相关慢性肝病急性加重住院的患者,用于开发新评分并在外部组验证。
  • 共954例符合COSSH-ACLF标准的HBV-ACLF患者纳入分析。

主要发现

  • 6项预测因子与28天死亡率显著相关,构成新评分公式:1.649×ln(INR)+0.457×肝性脑病评分+0.425×ln(中性粒细胞)+0.396×ln(总胆红素)+0.576×ln(血清尿素)+0.033×年龄。
  • 新评分28/90天死亡率C指数为0.826/0.809,显著高于COSSH-ACLF(0.793/0.784)、CLIF-C ACLF(0.792/0.770)、MELD(0.731/0.727)和MELD-Na(0.730/0.726),均p<0.05。
  • 新评分28天死亡率预测错误率显著低于其他4种评分:COSSH-ACLF(15.9%)、CLIF-C ACLF(16.3%)、MELD(35.3%)和MELD-Na(35.6%)。
  • 概率密度函数评估和风险分层显示新评分对死亡率具有最高预测价值,结果在外部队列中得到验证。

关键数值与推荐

  • HBV-ACLF诊断基于中国重型乙型肝炎研究组ACLF(COSSH-ACLF)标准。
  • 新评分公式中各因子系数:INR 1.649、肝性脑病评分0.457、中性粒细胞0.425、总胆红素0.396、血清尿素0.576、年龄0.033。

临床怎么用

  • 新评分可用于HBV-ACLF患者早期预后判断,指导临床管理并可能降低死亡率。
  • 新评分无需评估器官衰竭,简化了临床评估流程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Early determination of the prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is important to guide clinical management and decrease mortality. The aim of this study was to develop a new simplified prognostic score to accurately predict outcomes in patients with HBV-ACLF. METHODS: Prospective clinical data from 2,409 hospitalized patients with acute deterioration of HBV-related chronic liver disease were used to develop a new prognostic score that was validated in an external group. RESULTS: A total of 954 enrolled patients with HBV-ACLF were diagnosed based on the Chinese Group on the Study of Severe Hepatitis B-ACLF (COSSH-ACLF) criteria. Six predictive factors were significantly related to 28-day mortality and constituted a new prognostic score (=1.649×ln(international normalized ratio)+0.457×hepatic encephalopathy score+0.425×ln(neutrophil)+0.396×ln(total bilirubin)+0.576×ln(serum urea)+0.033×age). The C-indices of the new score for 28-/90-day mortality (0.826/0.809) were significantly higher than those of 4 other scores (COSSH-ACLF, 0.793/0.784; CLIF-C ACLF, 0.792/0.770; MELD, 0.731/0.727; MELD-Na, 0.730/0.726; all p <0.05). The prediction error rates of the new score for 28-day mortality were significantly lower than those of the 4 other scores: COSSH-ACLF (15.9%), CLIF-C ACLF (16.3%), MELD (35.3%) and MELD-Na (35.6%). The probability density function evaluation and risk stratification of the new score also showed the highest predictive values for mortality. These results were then validated in an external cohort. CONCLUSION: A new prognostic score based on 6 predictors, without an assessment of organ failure, can accurately predict short-term mortality in patients with HBV-ACLF and might be used to guide clinical management. LAY SUMMARY: Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a complex syndrome that is associated with a high short-term mortality rate. We developed a simplified prognostic score for patients suffering from this condition based on a prospective multicentre cohort. This new score had better predictive ability than 4 other commonly used scores.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Li J, Liang X, You S, et al. Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure. J Hepatol. 2021. PMID: 34090929. doi:10.1016/j.jhep.2021.05.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。